Abstract：【Objective】 To investigate the clinical effect of trimetazidine on hypertensive heart disease and its effect on oxidative stress index level.【Methods】Eighty-eight patients with hypercardiac disease were selected and divided into control group (routine antihypertensive, lipid-lowering, antiplatelet or anticoagulant therapy,n=48) and observation group (combined with trimetazidine on the basis of control group,n=40). The clinical effects and the changes of cardiac function (LVEF, LVESD, LVDD, LAD), oxidative stress (SOD, MDA, ROS) were compared between the two groups.【Results】The total effective rate of observation group was 90.00% (36/40), which was higher than that of control group (68.75%) (33/48). The difference was statistically significant (χ2=7.940,P=0.005<0.05). After treatment, the LVEF level of the two groups was higher than that before treatment, and the levels of LVESD, lad and LVDD were lower than those before treatment, and the differences between the two groups were statistically significant (mean P<0.05). After treatment, the serum SOD level of the two groups was higher than that before treatment, the MDA and ROS levels were lower than that before treatment, and the difference between the two groups was statistically significant (mean P<0.05). 【Conclusion】Trimetazidine can effectively assist in the treatment of high heart disease, improve the heart function of patients, and reduce the oxidative stress response of patients, which is worthy of clinical reference.
张娜, 刘霞, 王国伟. 曲美他嗪治疗高血压性心脏病的临床效果及对氧化应激指标水平的影响[J]. 医学临床研究, 2020, 37(6): 889-891.
ZHANG Na, LIU Xia, WANG Guo-wei. Clinical Effect of Trimetazidine in the Treatment of Hypertensive Heart Disease and its Effect on the Level of Oxidative Stress Index. JOURNAL OF CLINICAL RESEARCH, 2020, 37(6): 889-891.
[1] 吴平生. 高血压患者他汀治疗的临床思考[J]. 中华心血管病杂志,2017,45(1):3-4. [2] 宫丹丹. 曲美他嗪联合卡维地洛治疗风湿性心脏病伴心衰的临床效果观察[J].中国现代药物应用,2016,10(17):231-232. [3] Rehberger-Likozar A, ebe tjen M. Influence of trimetazidine and ranolazine on endothelial function in patients with ischemic heart disease[J].Coronary Art Dis,2015,26(8):651-656. [4] Fi Z, Kovács G, Szentes V. A trimetazidin szerepe a diabeteses microangiopathia kezelésében ischaemiás szívbetegség esetén[J].Orvosi Hetilap,2015,156(19):765-768. [5] 刘婷,王晓焕,尹昭,等. 曲美他嗪对伴有高血压的冠心病患者心脏舒张功能的影响[J].中国老年保健医学,2015,13(6):13-14. [6] 张成,高斌. 比索洛尔与曲美他嗪联用对高血压心肌肥厚患者心肌重构的抑制作用[J].中国生化药物杂志,2016,36(11):50-52. [7] Chen F, Liu F, Lu J, et al. Coenzyme Q10 combined with trimetazidine in the prevention of contrast-induced nephropathy in patients with coronary heart disease complicated with renal dysfunction undergoing elective cardiac catheterization: a randomized control study and in vivo study[J].Eur J Med Res,2018,23(1):45-47. [8] 武文君,宣玲,汪朝晖,等. 曲美他嗪对高血压性心脏病患者心肌重构和氧化应激水平的影响[J].中国药房,2018,29(1):89-93. [9] 曾志明. 曲美他嗪治疗老年高血压性心脏病慢性心力衰竭对心功能及预后的影响[J].中国实用乡村医生杂志,2017,24(11):64-66. [10] 杨婷,赵茜茜,崔晓博,等. 曲美他嗪联合芪苈强心胶囊治疗高血压心脏病慢性心力衰竭对患者炎性反应及血管活性物质的影响[J].宁夏医科大学学报,2017,39(6):699-701.
2020, Vol. 37 
